Brief: Cantargia Presents Positive Results Of Nadunolimab Combination Therapy

Cantargia AB

16/09/2024 07:59

Sept 16 (Reuters) - Cantargia AB (publ)  CANTA.ST :
    * ON SATURDAY PRESENTED POSITIVE RESULTS SHOWING BENEFIT OF
NADUNOLIMAB COMBINATION THERAPY IN CANCER AFTER RELAPSE ON
PD1-INHIBITORS
    * PRESENTED DATA FROM TWO CLINICAL TRIALS OF NADUNOLIMAB
COMBINATION THERAPY IN 55 PATIENTS WITH PRIMARILY LUNG CANCER
AND HEAD AND NECK CANCER
    * BOTH TRIALS SHOW E.G. VERY ENCOURAGING MEDIAN SURVIVAL
TIMES IN
PATIENTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY


        
 Source text for Workspace:  urn:newsml:reuters.com:*:nNDL4vPCfL
 Further company coverage:  CANTA.ST  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))